Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2015 December;27(4) > Minerva Biotecnologica 2015 December;27(4):219-23

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA BIOTECNOLOGICA

A Journal on Biotechnology and Molecular Biology


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246


eTOC

 

REVIEWS  


Minerva Biotecnologica 2015 December;27(4):219-23

language: English

SIGIRR/TIR8: a potential therapeutic target for inflammation treatment

Tejeda Gómez Y. 1, Pentón Rol G. 2, Fernández Massó J. R. 1

1 Pharmacogenomics Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba;
2 Clinical Trials Division, Center for Genetic Engineering and Biotechnology, Havana, Cuba


FULL TEXT  


Inflammation is a fundamental response to tissue injury and invasion of pathogens, but it is detrimental in clinically important inflammatory disorders. Despite the extended use of conventional anti-inflammatory drugs there is a need for new drugs and therapeutic targets to overcome the high risk disadvantages related to such use. SIGIRR/TIR8 is a phylogenetically conserved molecule which is widely expressed in the organism and plays a key role in innate immune response and T helper polarization. It regulates NF-kB pathway triggered by IL1R1 and TLRs. The ability to dampen signaling from ILRs and TLRs family members makes TIR8/SIGIRR a key regulator of inflammation. This review summarizes the most recent and outstanding evidences on SIGIRR/TIR8 expression and regulation which make this molecule a promising target for new drugs development in anti-inflammatory therapy against autoimmune diseases (e. g. systemic lupus erythematosus), rheumatoid arthritis, asthma, gut inflammation diseases and others.

top of page

Publication History

Cite this article as

Corresponding author e-mail